There is a growing consensus that the combination of anti-HER2 and endocrine therapies is an underutilized clinical option that may help overcome resistance, de-escalate the use of chemotherapeutics and improve patient survival in HER2+/ER+ breast cancer [6]. This evidence concerns the gene ESR1 and breast carcinoma.